Why Journalists Won’t Investigate the Trans Medical Industry -Gerald Posner (#15)
29 May 2025
With Gerald Posner
Global
Gerald Posner — Pulitzer finalist, former attorney and veteran pharma investigator — examines the trans medical industry through the same lens he applied to the opioid crisis. He traces how off-label prescribing loopholes, captured international guidelines and commercial incentives have driven the rapid medicalisation of gender-distressed young people. For Ireland, where HSE gender services have operated under WPATH-derived standards, his account of political interference in what should be clinical guidance raises direct questions about the evidence base underpinning Irish practice and the adequacy of informed consent for irreversible interventions.
Gerald Posner brings unusual credentials to the debate over gender medicine for young people. A Pulitzer Prize finalist, former attorney and veteran investigative journalist whose work has spanned some of the most consequential pharmaceutical controversies of recent decades, Posner examines the trans medical industry through the same analytical framework he has applied elsewhere — asking how profit motive, regulatory gaps and institutional capture allow practice to outrun evidence. The parallel he draws to the opioid crisis is central to his argument. He contends that the pharmaceutical industry has a recognisable playbook: cultivate clinical advocates, exploit off-label prescribing rules and secure a patient population requiring lifelong medication. Children who begin on puberty blockers, he argues, commonly progress to cross-sex hormones and, in many cases, surgery — generating sustained revenue for manufacturers, clinics and prescribers across the full arc of a patient's life. In the United States, puberty blockers have never received formal FDA approval for the treatment of gender dysphoria in minors; they are prescribed under a loophole permitting licensed drugs to be used for unapproved indications, bypassing the evidentiary threshold that regulatory approval would ordinarily demand. The WPATH emails discussed in the episode add a further dimension to this picture. Internal communications, Posner argues, show that political considerations and the influence of outside advocacy shaped what clinicians and policymakers then cited as independent clinical consensus. This matters acutely for Ireland because HSE gender services, like counterparts across much of Europe, have operated under guidelines derived from WPATH standards rather than from independently commissioned national evidence reviews. If those international standards were shaped as much by ideology as by evidence, the basis on which informed consent is obtained in Irish clinics deserves serious scrutiny. Postner is equally forensic about the failure of mainstream journalism to hold any of this to account. Reporters willing to pursue pharmaceutical wrongdoing in other therapeutic areas have largely steered clear of gender medicine, he suggests, deterred by editorial caution, activist pressure and the professional costs of dissent. The result is an information vacuum that has served the interests of both industry and ideology, leaving parents, clinicians and policymakers without the critical coverage they need to make sound decisions. From an Irish standpoint, the structural concerns Posner raises are not remote abstractions. The HSE has been in the process of reviewing and restructuring its paediatric gender services, and Ireland, like other countries, must decide what evidentiary standards it will apply to interventions with permanent effects on young bodies. Posner's core argument is that the mechanisms enabling pharmaceutical overreach — lobbying, off-label loopholes, captured international guidelines and the silencing of professional dissent — are not confined to any single jurisdiction. They travel with the conferences, the training programmes and the funding streams that connect Dublin to London to Washington. Recognising that pattern is a precondition for responding to it effectively.
